Company intelligence / Profile preview

Sunbird Trust

Cambridge, Massachusetts, United Statessunbirdtrust.com ↗

Ownership: Private
Development stage: Other

Overview

Sunbird Bio has demonstrated the ability to directly detect and differentiate key aggregated proteins implicated in neurodegenerative diseases using a simple blood draw. Their technology is positioned to improve early diagnosis, patient stratification, monitoring, and drug development for Alzheimer’s disease, Parkinson’s disease, other neurological disorders, and early-stage cancer. Clinical studies are ongoing; no commercial products yet.

Therapeutic areas: OncologyNeurology
Modalities: Diagnostic platformProtein-based diagnosticsBlood-based diagnostics
Industry: Protein Biomarker Diagnostics

Partnerships

Eli Lilly and CompanyEDBIClavystBioPolaris PartnersSection32/S32

Beyond the preview

Go deeper on Sunbird Trust.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sunbird Trust.

Explore the full profile